PCOs patients 18–38 years in two groups; treatment () and placebo ()
1.5 g/d supplements or placebo (4 capsules of 125 mg, TDS)
Significant improvement in menstrual cyclicity in cinnamon group compared with baseline and placebo. Menstrual bleeding was resulted from ovulatory cycle because of luteal phase progesterone levels (>3 ng/ml) in 5 samples in the cinnamon group No considerable changes in markers of insulin resistance, serum androgen, SHBG levels, weight and ovarian volume in both groups.
15–45 years married women using DMPA and without menstrual bleeding for 45–140 days prior in three groups; fennel essential oil (FEO, ), LD-COC () and placebo ()
Each pack contained 21 LD-COC pills + 42 placebo capsules, 21 placebo pills + 42 fennel capsules, 21 placebo pills and 42 placebo capsules One pill and a capsule BID
Experience of menstrual bleeding in 73% of women in the FEO and 81% of women in LD-COC groups which markedly higher than the placebo group (19%), but no significant alteration between fennel and LD-COC groups ↑ mean amount of menstrual bleeding in the FEO group (21 cc) compared to the LD-COC (14 cc) and placebo (12 cc) groups ↑ duration of menstrual bleeding/spotting and the number of used sanitary pads in the FEO group (5.2 days, 10.4 pads) compared to the LD-COC (4 days, 7.4 pads) and placebo (4 days, 6.8 pads) groups ↓ mean duration of drug using in fennel group (14 days) compared to LD-COC (21 days) and placebo (20 days) groups () ↑ injections of DMPA after intervention in fennel (73%) and LD-COC groups (65%) compared to placebo group (31%).
Ethanolic extract of dried plant powder prepared as syrup
Double-blind, randomized, placebo-controlled, multi center study
18–35 years women with secondary amenorrhea and oligomenorrhea () in two groups; treatment () and placebo ()
45 ml of plant extract or placebo syrup TDS (in treatment group: 300 mg ethanol extract of plant in 5 ml of syrup)
three menstrual cycles
68.3% patients in the treatment and 13.6% in the placebo group experienced uterus bleeding during the first cycle (), regular bleeding during three cycles in one third of the patients treated with the herbal syrup (33.3%) compared to placebo (3.3%). ↓ LH in treatment group compared to placebo (), no changes in other hormonal parameters in both groups.
Anovulatory women with high plasma LH levels (PCOs = 38 and non PCOs = 62) in two groups; control () and treatment ()
↓ LH (mean rate = 22.2 ± 35.7% in PCOs and 49.7 ± 15.3% in non- PCOs patients) and ↑ estradiol in unkei-to treatment group Development of the dominant follicle in patients treated with unkei-to. Improvement in menstrual cyclicity (50% in PCOs and 60% in the non-PCOs group) in unkei-to treatment group but no significant difference between the two groups.
20 to 40 years old women with oligomenorrhea and complaint of more than 2 weeks menstruation retard
60 g powdered with a tea spoon of honey once daily before breakfast
Experience of menstrual bleeding in 85% of the patient after treatment within two weeks Higher volume of menstrual bleeding in 20% () of the patient after treatment Drug-free episode of menstruation in 80% of the patient in less than 2 weeks.
Women with oligomenorrhea in two groups; progesterone () and sesame group ()
60 g sesame powdered once daily or Medroxy Progesterone 5 mg tablets BID
Occurrence of menstrual bleeding in 72% of the patient in the sesame group and 93.10% in the progesterone group (significantly higher than the sesame group, ) No marked increasing in volume of blood flow and severity of pain in both groups ↓ duration of drug using for experiencing menstrual bleeding in sesame group compared to progesterone group (10.38 days versus 11.8) On-time menstruation in drug-free episode in 50% of the patients in sesame group compared to 6% in progesterone group.
20–35 year-old women with PCOs + menstrual disturbances and infertility ± clinical signs of hyperandrogenism chief complaints in two groups; treatment () and placebo ()
500 mg of extract or placebo BID plus metformin TDS
↓ significant in polycystic-appearing ovaries in ultrasound scans in extract group after treatment () No significant changes in BMI, markers of insulin resistance (HOMA-IR) and insulin sensitivity (QUICKI), testosterone and 17-α OHP levels, F-G score in both groups. Normalizing menstrual cycle in 12 women with oligo-amenorrhea in extract group.
Open-label, single arm, non-randomized, clinical study
Premenopausal women (18–45 years) with PCOs
2 capsule of 500 mg daily
↑ LH () and ↑ FSH (), ↓ LH/FSH ratio (3.16 to 1.61), but not significant ↓ left & right ovary volume (↓17.82% & 28.25%), ↓ cyst size in 47 subjects, no cyst in 36 subjects, regular cycles in 71% of subjects, ↑ Hb levels, ↓ ALP, no significant change in WBC, AST, ALT, BUN and creatinine and 12% pregnancy after treatment compared to the baseline.
Hyperandrogenism female in two groups; experimental (extract, ) and control (standard treatment, )
300–600 mg of plant dried extract or cyproterone compound and Spironolactone
↓ total, free testosterone () and DHEA () after treatment in the experimental group No significant difference between the study parameters (total, free testosterone and DHEAS) in two groups ↑ improvement of acne, greasy skin (), menstrual cycle situation () in the control group compared to the experimental group after the treatment.
Randomized, placebo-controlled clinical double-blind study
Women with oligomenorrhea () or amenorrhea () in two groups; treatment and placebo
50 drops of Phyto Hypophyson L or placebo TDS
3 months or 3 cycles
Occurrence of menstruation and shortening of the cycle in the treatment group compared to the placebo. ↑ luteal phase progesterone in oligomenorrheal women after treatment relative to placebo. Improvement of ovulation and 38 pregnancy out of 67 women in the treatment group compared to the placebo.
Randomized, triple-blind clinical trial with a placebo controlled
Women 18–45 years old with PCOS and oligomenorrhea or amenorrhea in two equal groups; LD and Vitex agnus-castus groups
Capsule contained LD pill or extract daily
Normalization the menstrual cycle duration in 68.6% of the LD group members and 60% of the extract participants without considerable difference between the two groups () ↓ means of the free testosterone, prolactin and DHEAS level in the LD and the extract groups after treatment, but no significant difference between the two groups.